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studies; the comparison also shows common recent development
of bayesian decision models and choices of appropriate weight-
ing of prior information (e.g. use of mixture prior information
for judging similarity by the “positive treatment effect” in clinical
research or use of different weighting between individual and
population level for the ﬁnancing studies). Moreover, selection of
appropriate weighting in both types of studies face regulators
and ﬁnancing agencies that need to have conﬁdence in the trans-
ferability of their results between regions. CONCLUSIONS:
New developments of statistical analysis especially Bayesian
evaluation both in global clinical research and social sciences can
lead to a better integration of types of research designs. They can
improve scientiﬁc evidence for health care policy decision pro-
cesses. Context free research is not sufﬁcient to integrate the
effect of environmental modiﬁers (like in asthma) or variations in
social and political processes (e.g. variation in exemption criteria
especially during health reforms or systems in transition).
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OBJECTIVE: This study attempted to determine if select patient
and physician demographic variables are predictors of the pre-
scribing of asthma pharmacotherapy in the ambulatory patient
population of the United States, with particular emphasis on the
non-African American minority population. Recent research sug-
gests that these populations may be at-risk for receiving sub-
optimal asthma care due to cultural and/or linguistic barriers to
obtaining proper care, cultural beliefs about asthma treatment,
low socio-economic status and even genetic polymorphisms that
lead to poor responses to asthma medications. METHODS: This
study was a retrospective cross-sectional study that used data
from the National Ambulatory Medical Care Survey (NAMCS)
from 1998 through 2004. The weighted population sample size
of the study was 82,020,318 patients and there were 1,540
observations in this study (pre-weighted sample size). Speciﬁc
patient demographic variables, physician demographic variables
and asthma medications prescribed were extracted from the
dataset and analyzed. RESULTS: A major ﬁnding from this study
was the fact that non-African American minority populations
were receiving sub-optimal asthma pharmacotherapy. Non-
African American minorities (Asians, Native Americans, Paciﬁc
Islanders, Alaskan Natives and other minorities) were less likely
to be prescribed controller medications (OR = 0.405), combina-
tions of ICS and LABA agents (OR = 0.267) and more likely to
be prescribed SABA agents (OR = 1.769) when compared to the
overall population [all p < 0.05]. Additionally, our research also
indicates that these minority patients are generally younger, more
likely to see primary care physicians, and are also likely to have
insurance coverage (public & private). They are also more likely
to reside in an urban area and live in the Western United. States.
CONCLUSION: It appears that a more concerted effort needs
to be undertaken to study the factors that may explain the
sub-optimal patterns of asthma care provided to these at-risk
minority populations.
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OBJECTIVE: To evaluate the impact of psoriasis (PsO) on the
presence of co-morbidities in the ﬁrst year after the diagnosis.
METHODS: A retrospective study of the PharMetrics database,
compiled from managed care plans throughout the United States,
from January 1, 2000 through December 31, 2006 was con-
ducted. Patients between the ages of 18 to 80 years, who had a
minimum of 12 months of continuous enrollment before and
after their index diagnosis with PsO, were included. The index
diagnosis date was derived from the ﬁrst claim for PsO during the
study period. The presence of co-morbidities was determined by
frequency counts and as a percentage of total claims generated
during the study period. RESULTS: The study cohort included
48,068 patients; 52.3% were females, and the mean age was
46.3 years. Multiple co-morbidities were identiﬁed in the years
prior to and subsequent to the diagnosis of PsO. The ﬁve most
frequently observed co-morbidities were: hypertensive disease
(increased from 24.45% to 26.65%), hyperlipidemia (from
15.72% to 18.06%), pure hypercholesterolemia, pure hyperglyc-
eridemia, and mixed hyperlipidemia (from 14.65% to 16.18%),
diabetes mellitus (from 8.36% to 9.57%), depressive disorder,
episodic mood disorder, and dysthemic disorder (from 6.88% to
7.12%). Additionally, the ﬁve highest percentage increases in
co-morbidities in the years prior to and subsequent to the diag-
nosis of PsO were: 1) Malignant neoplasm of uterus and cervix
uteri (60%, pre-n = 26, post-n = 38); 2) Malignant neoplasm of
trachea, bronchus and lung (57.1%, pre-n = 33, post-n = 54); 3)
Malignant neoplasm of ovary and other uterine adnexa (44.4%,
pre-n = 42, post-n = 63); 4) Psoriatic Arthropathy (44.0%, pre-
n = 1357, post-n = 1950); and 5) Atherosclerosis (33.3%, pre-
n = 142, post-n = 193). CONCLUSION: This study indicates
that co-morbidities increase signiﬁcantly in the year subsequent
to a diagnosis of PsO. The large increases noted in malignancies
may be due to the small numbers of cases observed.
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OBJECTIVE: Five biological treatments are registered for pso-
riasis, the tumor necrosis alpha (TNF-alpha) inhibitor adali-
mumab, etanercept and inﬂiximab and the T-cell modulator
alefacept, efalizumab. Our objectives were to analyse the efﬁcacy
of registered biological drugs in psoriasis and also to compare
their efﬁcacy on a pharmacological group level. METHODS:
Cochrane Highly Sensitive Search Strategy was used to identify
RCTs in MEDLINE. Inclusion criteria were: a) treatment of
psoriasis b) outcome data on the proportions of patients achiev-
ing at least 75% improvement in Psoriasis Area and Severity
Index (PASI) from baseline. The quality of selected studies was
measured using the Jadad-score. Data were entered into Review
Manager 4.2 software. The chosen summary statistic variable
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